Fusion Pharmaceuticals Inc expected to post a loss of 33 cents a share - Earnings Preview

Fusion Pharmaceuticals

12/03/2024 12:43

* Fusion Pharmaceuticals Inc  FUSN.OQ   FUSN.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 14 (estimated) for the period ending December 31 2023
    * The Hamilton Ontario Ontario-based  company is expected to
report a 192.8% increase in revenue to $409.9 thousand from $140
thousand a year ago, according to the mean estimate from 10
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Fusion Pharmaceuticals
Inc is
for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $15.00​, above​ its last closing price
of $9.42. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.39       -0.40      -0.25     Beat    37.4
 Jun. 30 2023  -0.38       -0.39      -0.38     Beat    2.3
 Mar. 31 2023  -0.32       -0.32      -0.45     Missed  -41.7​
 Dec. 31 2022  -0.56       -0.56      -0.55     Beat    1.1
 ​​Sep.        -0.51       -0.50      -0.55     Missed  -10
 30 2022                                                
 Jun. 30 2022  -0.53       -0.53      -0.44     Beat    17.4​
 Mar. 31 2022  -0.47       -0.48      -0.46     Beat    4.2
 Dec. 31 2021  -0.42       -0.47      -0.40     Beat    14.3
 This summary was machine generated March 12 at 12:43 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)